Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC
Автор: ecancer
Загружено: 2025-02-26
Просмотров: 242
Описание:
Prof Thomas Powles speaks to ecancer about EV-302: an updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab compared to chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
This study shows that the combination of enfortumab vedotin and pembrolizumab offers better response rates than traditional chemotherapy for metastatic bladder cancer.
With a median follow-up of two and a half years, about 30% of patients achieve a complete response, indicating improved survival rates.
Future research aims to enhance cure rates and explore bladder-sparing strategies.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
